Stocktoria
Veradermics, Inc MANE
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2026-02-04
Veradermics, Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | $62.1M | $23.3M |
| Operating income | -$72.3M | -$26.8M |
| Income tax | $0 | $0 |
| Net income | -$70.0M | -$26.5M |
| EPS (diluted) | $-111.91 | $-37.05 |
| Operating cash flow | -$71.6M | -$23.7M |
| Free cash flow | -$71.6M | -$23.7M |
| Cash & equivalents | $21.8M | $53.1M |
| Total assets | $152.6M | $55.5M |
| Total liabilities | $9.2M | $4.7M |
| Shareholders' equity | -$121.0M | -$48.5M |
Source: SEC EDGAR filings · CIK 0001827635 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.